Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Redwood Regional Medical Group, Inc.
mi
from
Santa Rosa, CA
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Redwood Regional Medical Group, Inc.
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Advanced Urology, PC
mi
from
Parker, CO
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Advanced Urology, PC
mi
from
Parker, CO
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Manatee Medical Research Institute, LLC
mi
from
Bradenton, FL
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Manatee Medical Research Institute, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Baptist Cancer Institute
mi
from
Jacksonville, FL
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Baptist Cancer Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Midwestern Regional Medical Center
mi
from
Zion, IL
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Midwestern Regional Medical Center
mi
from
Zion, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Detroit Clinical Research Center
mi
from
Lansing, MI
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Detroit Clinical Research Center
mi
from
Lansing, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Adult and Pediatric Urology
mi
from
Sartell, MN
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Adult and Pediatric Urology
mi
from
Sartell, MN
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Montefiore Medical Center
mi
from
Bronx, NY
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Accumed Research Associates
mi
from
Garden City, NY
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Accumed Research Associates
mi
from
Garden City, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Hendrick Cancer Center
mi
from
Abilene, TX
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Hendrick Cancer Center
mi
from
Abilene, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Oncology Consultants
mi
from
Houston, TX
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Oncology Consultants
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Virginia Mason Medical Center
mi
from
Seattle, WA
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated:  4/24/2018
Medical Oncology Associates PS
mi
from
Spokane, WA
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
Status: Enrolling
Updated: 4/24/2018
Medical Oncology Associates PS
mi
from
Spokane, WA
Click here to add this to my saved trials
Partnership for Healthy Seniors
Cancer Prevention and Treatment Among African American Older Adults: Screening Trial
Status: Enrolling
Updated:  4/24/2018
Bloomberg School of Public Health
mi
from
Baltimore, MD
Partnership for Healthy Seniors
Cancer Prevention and Treatment Among African American Older Adults: Screening Trial
Status: Enrolling
Updated: 4/24/2018
Bloomberg School of Public Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies
Status: Enrolling
Updated:  4/25/2018
National Cancer Institute
mi
from
Bethesda, MD
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies
Status: Enrolling
Updated: 4/25/2018
National Cancer Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies
Status: Enrolling
Updated:  4/25/2018
Memorial Sloan-Kettering
mi
from
New York, NY
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies
Status: Enrolling
Updated: 4/25/2018
Memorial Sloan-Kettering
mi
from
New York, NY
Click here to add this to my saved trials
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies
Status: Enrolling
Updated:  4/25/2018
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies
Status: Enrolling
Updated: 4/25/2018
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy
Status: Enrolling
Updated:  4/26/2018
Veterans Administration Los Angeles Healthcare System
mi
from
Los Angeles, CA
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy
Status: Enrolling
Updated: 4/26/2018
Veterans Administration Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy
Status: Enrolling
Updated:  4/26/2018
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy
Status: Enrolling
Updated: 4/26/2018
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Focal Laser Ablation of Prostate Tissue
Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance
Status: Enrolling
Updated:  4/26/2018
UCLA
mi
from
Los Angeles, CA
Focal Laser Ablation of Prostate Tissue
Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance
Status: Enrolling
Updated: 4/26/2018
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Focal Laser Ablation of Prostate Tissue
Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance
Status: Enrolling
Updated:  4/26/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Focal Laser Ablation of Prostate Tissue
Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance
Status: Enrolling
Updated: 4/26/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated:  4/26/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated: 4/26/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated:  4/26/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated: 4/26/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated:  4/26/2018
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated: 4/26/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated:  4/26/2018
University of California at San Francisco
mi
from
San Francisco, CA
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated: 4/26/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study
Status: Enrolling
Updated:  4/27/2018
UCLA
mi
from
Los Angeles, CA
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study
Status: Enrolling
Updated: 4/27/2018
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
Providence Portland Medical Center
mi
from
Portland, OR
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
John Wayne Cancer Institute
mi
from
Santa Monica, CA
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
University of Miami
mi
from
Coral Gables, FL
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
University of Miami
mi
from
Coral Gables, FL
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
Tasman Oncology Research
mi
from
Southport,
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
Tasman Oncology Research
mi
from
Southport,
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
Advocate Health
mi
from
Niles, IL
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
Advocate Health
mi
from
Niles, IL
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated:  4/30/2018
UT Southwestern
mi
from
Dallas, TX
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Status: Enrolling
Updated: 4/30/2018
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Phase 1b Study of ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Status: Enrolling
Updated:  5/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Phase 1b Study of ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Status: Enrolling
Updated: 5/1/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Status: Enrolling
Updated:  5/1/2018
Meharry Medical College
mi
from
Nashville, TN
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Status: Enrolling
Updated: 5/1/2018
Meharry Medical College
mi
from
Nashville, TN
Click here to add this to my saved trials
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Status: Enrolling
Updated:  5/1/2018
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Status: Enrolling
Updated: 5/1/2018
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Status: Enrolling
Updated:  5/1/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Status: Enrolling
Updated: 5/1/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Status: Enrolling
Updated:  5/1/2018
Chris O'Brien Lifehouse
mi
from
Camperdown,
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Status: Enrolling
Updated: 5/1/2018
Chris O'Brien Lifehouse
mi
from
Camperdown,
Click here to add this to my saved trials